Strs Ohio Sells 20,600 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Strs Ohio lowered its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 16.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,800 shares of the medical instruments supplier’s stock after selling 20,600 shares during the period. Strs Ohio owned approximately 0.25% of Harvard Bioscience worth $560,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. B. Riley Asset Management LLC grew its stake in Harvard Bioscience by 6.5% in the 3rd quarter. B. Riley Asset Management LLC now owns 3,262,995 shares of the medical instruments supplier’s stock worth $14,031,000 after buying an additional 200,032 shares in the last quarter. AMH Equity Ltd grew its stake in Harvard Bioscience by 7.1% in the 3rd quarter. AMH Equity Ltd now owns 2,141,353 shares of the medical instruments supplier’s stock worth $9,208,000 after buying an additional 141,353 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Harvard Bioscience by 64.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 161,819 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 63,174 shares in the last quarter. Acuitas Investments LLC grew its stake in Harvard Bioscience by 34.1% in the 3rd quarter. Acuitas Investments LLC now owns 241,781 shares of the medical instruments supplier’s stock worth $1,040,000 after buying an additional 61,481 shares in the last quarter. Finally, Punch & Associates Investment Management Inc. grew its stake in Harvard Bioscience by 2.1% in the 3rd quarter. Punch & Associates Investment Management Inc. now owns 2,923,034 shares of the medical instruments supplier’s stock worth $12,569,000 after buying an additional 60,385 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

HBIO stock opened at $3.62 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.85 and a quick ratio of 0.92. Harvard Bioscience, Inc. has a one year low of $3.44 and a one year high of $6.29. The stock has a market cap of $157.11 million, a PE ratio of -45.24 and a beta of 1.42. The firm has a 50 day simple moving average of $4.23 and a two-hundred day simple moving average of $4.47.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $28.15 million during the quarter, compared to the consensus estimate of $27.80 million. Harvard Bioscience had a positive return on equity of 2.75% and a negative net margin of 3.04%. On average, analysts predict that Harvard Bioscience, Inc. will post 0.14 EPS for the current fiscal year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.